We are live on ! Find out more
AA

ALPS Advisors Portfolio holdings

AUM $21.3B
1-Year Est. Return 21.71%
This Fund
S&P 500
This Quarter Est. Return
-2.6%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$9.68B
AUM Growth
-$563M
Cap. Flow
-$165M
Cap. Flow %
-1.7%
Top 10 Hldgs %
52.24%
Holding
834
New
152
Increased
118
Reduced
346
Closed
218

Sector Composition

Rank Sector Weight
1 Energy 67.04%
2 Financials 2.89%
3 Materials 2.22%
4 Healthcare 2.17%
5 Technology 1.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SIOX
176
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.28M 0.01%
13,938
-2,389
-15% -$255K
FRT icon
177
Federal Realty Investment Trust
FRT
$10.9B
$1.27M 0.01%
8,144
-285
-3% -$42.6K
ACHN
178
DELISTED
Achillion Pharmaceuticals
ACHN
$1.19M 0.01%
153,668
-26,209
-15% -$192K
UDR icon
179
UDR
UDR
$12.9B
$1.19M 0.01%
30,767
-1,301
-4% -$46.5K
MAC icon
180
Macerich
MAC
$7.32B
$1.18M 0.01%
14,948
-1,560
-9% -$122K
SAGE
181
DELISTED
Sage Therapeutics
SAGE
$1.15M 0.01%
36,008
-2,013
-5% -$70.9K
SLG icon
182
SL Green Realty
SLG
$3.88B
$1.14M 0.01%
12,147
-451
-4% -$41.2K
SCLN
183
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$1.13M 0.01%
102,322
+35,240
+53% +$313K
PDLI
184
DELISTED
PDL BioPharma, Inc.
PDLI
$1.1M 0.01%
330,907
+22,464
+7% +$70K
XLRN
185
DELISTED
Acceleron Pharma
XLRN
$1.1M 0.01%
41,718
-2,087
-5% -$60.7K
ENTA icon
186
Enanta Pharmaceuticals
ENTA
$372M
$1.09M 0.01%
37,000
+466
+1% +$13K
PAAS icon
187
Pan American Silver
PAAS
$18.6B
$1.07M 0.01%
98,528
-31,206
-24% -$267K
SCMP
188
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$978K 0.01%
89,478
+11,092
+14% +$140K
ASRT
189
DELISTED
Assertio
ASRT
$954K 0.01%
1,142
-186
-14% -$172K
KDNY
190
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$911K 0.01%
14,221
-2,436
-15% -$197K
ONCE
191
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$899K 0.01%
30,448
-2,107
-6% -$66.5K
FWP
192
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$889K 0.01%
7,473
-1,281
-15% -$144K
SUPN icon
193
Supernus Pharmaceuticals
SUPN
$2.68B
$839K 0.01%
55,019
-34,160
-38% -$446K
IMGN
194
DELISTED
Immunogen Inc
IMGN
$834K 0.01%
97,910
-16,680
-15% -$141K
DVAX
195
DELISTED
Dynavax Technologies
DVAX
$831K 0.01%
43,213
-7,405
-15% -$150K
CLVS
196
DELISTED
Clovis Oncology, Inc.
CLVS
$827K 0.01%
43,096
-7,385
-15% -$156K
REG icon
197
Regency Centers
REG
$15B
$822K 0.01%
10,986
-552
-5% -$39.5K
MGNX icon
198
MacroGenics
MGNX
$235M
$724K 0.01%
38,588
-6,613
-15% -$126K
CPGX
199
DELISTED
COLUMBIA PIPELINE GROUP IN COM STK (DE)
CPGX
$686K 0.01%
27,320
-155,502
-85% -$3.01M
IWO icon
200
iShares Russell 2000 Growth ETF
IWO
$14.5B
$667K 0.01%
4,915
-650
-12% -$81.1K

Similar funds

ALPS Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, ALPS Advisors held 834 positions worth $9.68B, down 5.5% from $10.2B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

ALPS Advisors's Q1 2016 filing shows 152 new, 118 increased, 346 reduced and 218 closed positions. Its largest new stake was ANTERO MIDSTREAM PARTNERS LP: 3,928,591 shares worth $86.9M. The largest sale was TARGA RESOURCES PARTNERS LP COM UTS REPTG LTD PARTERSHIP INT, an estimated $215M.

By sector, the portfolio is most concentrated in Energy at 67% of assets, down from 68% a quarter earlier, followed by Financials and Materials.

  • ALPS Advisors's largest Q1 2016 buy was ANTERO MIDSTREAM PARTNERS LP: 3,928,591 shares worth $86.9M.
  • ALPS Advisors added most to Energy Transfer Partners L.p. in Q1 2016, an estimated $275M increase.
  • ALPS Advisors's biggest Q1 2016 reduction was Oneok Partners LP, cutting an estimated $50.8M.
  • ALPS Advisors fully exited TARGA RESOURCES PARTNERS LP COM UTS REPTG LTD PARTERSHIP INT in Q1 2016, selling an estimated $215M.
  • ALPS Advisors's ten largest holdings make up 52% of its $9.68B portfolio in Q1 2016.
  • ALPS Advisors opened 152 new positions and closed 218 in Q1 2016.
  • ALPS Advisors's portfolio value fell 5.5% quarter-over-quarter to $9.68B.

Based on ALPS Advisors's 13F filing for Q1 2016, filed 10 May 2016.